Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Recent studies highlight the critical role of virus-specific T-cells in treating progressive multifocal leukoencephalopathy. Pre-existing T-cells predict superior responses to checkpoint inhibitors, while allogeneic T-cell transfer offers a
The 10-year follow-up of the APPAC trial demonstrates that antibiotic therapy remains a safe and effective alternative to appendectomy for uncomplicated acute appendicitis, with over 60% of patients successfully avoiding surgery for a decad
A secondary analysis of the DANFLU-2 trial demonstrates that high-dose influenza vaccines significantly reduce cardiorespiratory and influenza-related hospitalizations in adults aged 65 and older, with consistent benefits observed in patien
A landmark systematic review of over 48,000 patients reveals that while the proportion of AIFRS in immunocompromised populations is increasing, mortality rates have dropped significantly since 2013 due to diagnostic and therapeutic advancem
A comprehensive meta-analysis reveals that while the proportion of AIFRS in immunocompromised patients has risen to 16.6% in recent years, mortality has significantly decreased to 28.2% due to improved diagnostic and therapeutic strategies.
A phase 4 trial in The Gambia reveals that maternal Tdap-IPV vaccination provides early mucosal IgG to infants, while the DTwP primary series induces significantly stronger mucosal antibody and T-cell responses than DTaP, despite maternal a
A large-scale multicentre clinical trial reveals that 5% permethrin cream is significantly more effective than oral ivermectin for treating scabies in households, providing crucial evidence for public health and clinical practice.
A multicenter stepped-wedge trial reveals that while prospective audit and feedback by stewardship teams improves the quality of discharge antibiotic prescribing, it fails to reduce the overall volume or duration of therapy, highlighting th
A randomized multimethod study reveals that while AI clinical decision support systems for antibiotic switching are well-received, their primary influence is reinforcing conservative prescribing. The study underscores that usability and cli
The Phase 2b INSIGHT study demonstrates that twice-daily bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF) is highly effective and safe for treating HIV in patients receiving rifampicin-based tuberculosis therapy, achieving over 94
A Phase 1 trial confirms that the HeV-sG-V vaccine is safe and, when administered in a two-dose 100 μg regimen, induces high levels of neutralizing antibodies against both Bangladesh and Malaysia strains of the Nipah virus.
A groundbreaking clinical trial reveals that a novel nasal vaccine, BPZE1, can prevent Bordetella pertussis colonization, offering a potential solution to the transmission gaps in current whooping cough immunization programs.
Large-scale trials in Kenya and Mozambique demonstrate that ivermectin mass drug administration significantly reduces malaria incidence by 26% and lowers community scabies prevalence, providing both direct protection and indirect herd-like
The Phase 2b PanACEA-DECODE-01 trial identifies delpazolid 1200 mg once daily as an effective and safer oxazolidinone alternative to linezolid, demonstrating a 38% faster mycobacterial load decline when added to a bedaquiline, delamanid, an
The Phase 2b PanACEA-SUDOCU-01 trial demonstrates that sutezolid significantly increases the bactericidal activity of a bedaquiline-delamanid-moxifloxacin regimen in pulmonary tuberculosis, notably without the neuropathy or myelosuppression
A landmark phase 2a trial in Laos identifies emodepside as a highly effective, weight-independent treatment for Strongyloides stercoralis, achieving cure rates of 89% at a 15 mg dose, matching the current gold standard ivermectin with a rob
GSK has announced positive Phase III results for Bepirovirsen, an antisense oligonucleotide that achieves functional cure in chronic hepatitis B patients. By targeting viral RNA and HBsAg, the drug offers a finite treatment path, potentiall
The 2023 WHO EGASP study highlights a critical rise in ceftriaxone-resistant gonorrhea in Southeast Asia, with resistance reaching 20% in some regions. These findings underscore the urgent need for enhanced global surveillance and the accel
This phase 3 trial demonstrates that oral zoliflodacin is a viable, non-inferior alternative to ceftriaxone plus azithromycin for treating uncomplicated urogenital gonorrhoea, offering a critical solution to rising antibiotic resistance.
The GBD 2023 study highlights a 33.4% reduction in pediatric LRI mortality since 2010, yet 2.5 million annual deaths persist. While Streptococcus pneumoniae remains the primary pathogen, newly modeled aetiologies like non-tuberculous mycoba
Open language-specific specialty feeds and department pages.